Fawaz Al-Mufti, M.D., associate professor of neurology, neurosurgery and of radiology, received a $172,517 grant from Cerus Endovascular, Inc. for "NECC: US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair."
Mitchell Cairo, M.D., professor of pediatrics, medicine, cell biology and anatomy and of pathology, microbiology and immunology, received a $1,004,658 grant from AbbVie Inc. for "A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms.”
HeePeel Chang, M.D., clinical assistant professor of surgery, received a $5,000 grant from the Society for Vascular Surgery for "Efficacy and Safety of Intravascular Lithotripsy in Treatment of Chronic Limb-Threatening Ischemia."
George Coritsidis, M.D., professor of medicine, received a $7,000 grant from Natera, Inc., for "Renasight Testing in Underserved immigrant population with CKD of unknown etiology from Central and South America."
Victor Garcia, Ph.D., assistant professor of pharmacology, received a $56,000 grant for "Interdisciplinary Basic Medical School Sciences Program" and a $16,000 grant for "MAP to Success: A Medical Application Preparation Program at New York Medical College (NYMC)" from the Association of Medical Schools.
Jessica Hochberg, M.D., associate professor of pediatrics, received a $9,500 grant from CHOP for “ADVL1711 A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors.”
David Kronn, M.D., associate professor of pediatrics and of pathology, microbiology and immunology, received a $845,000 grant from Sanofi, Inc., for "Baby-COMET: Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa."
Delong Liu, M.D., Ph.D., professor of medicine, received a $41,516 grant from MorphoSys for “REAL-MIND: Prospective multicenter observational study of patients with relapsed or refractory diffuse large B-cell lymphoma starting second- or third-line therapy and not receiving autologous stem cell transplant.”
Srihari Naidu, M.D., professor of medicine, received a $92,211 grant from Cytokinetics, Inc. for “Protocol CY 6031 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate The Efficacy And Safety Of CK3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy nd Left Ventricular Outflow Tract Obstruction.”
Sheila Nolan, M.D., assistant professor of pediatrics, received a $22,096 grant from the NIH for "Comparative Effectiveness and Complications of Intravenous Ceftriaxone Compared with Oral Doxycycline in Lyme Meningitis in Children.”
Lance Parton, M.D., professor of pediatrics and associate professor of anesthesiology and of obstetrics and gynecology, received a $50,000 grant from the NIH for "Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (SILDI-SAFE).”
Tana Pradhan, D.O., clinical associate professor of obstetrics and gynecology, received a $103,545 grant from K-Beta Group, Inc/GOG Foundation for "A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alternations (Protocol ZN-c3-005)."
Karen Seiter, M.D., professor of medicine, received a $85,935 grant for "Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy” and a $65,620 grant for "A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome" (SELECT MDS-)" from Syros Pharma/CRO Precision for Medicine.
Gregory Veillette, M.D., assistant professor of surgery, received a $117,449 grant from Imvax, Inc. for "Evaluation of Immunological Responses Against Hepatocellular Carcinoma (Hcc) Tumors.”
John Welter, M.D., assistant professor of pediatrics, received a $288,790 grant from AbbVie for “A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation” and a $195,118 grant from Vertex Pharmaceuticals for “A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of Vx-121 Combination Therapy in Subjects with Cystic Fibrosis.”
Steven Wolf, M.D., clinical professor of pediatrics, received a $15,040 grant from Eisai for “Extended Access Program and Retrospective Chart Review For Locaserin in Dravet Syndrome and Other Refractory Epilepsies."